Items where authors include "Stapelkamp, C."

Article

Bullement, A. orcid.org/0000-0001-7091-0972, Nathan, P., Willis, A. et al. (6 more authors) (2019) Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma. PharmacoEconomics - Open, 3 (3). pp. 377-390. ISSN 2509-4262

Proceedings Paper

Bharmal, M., Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). In: Annals of Oncology. 43rd ESMO Congress (ESMO 2018), 19-23 Oct 2018, Munich, Germany. Elsevier , p. 461.

Bullement, A. orcid.org/0000-0001-7091-0972, Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Modelling overall survival in immunotherapy using parametric techniques : Avelumab in previously treated metastatic Merkel cell carcinoma. In: Value in Health. ISPOR 21st Annual European Meeting, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S11-S11.

Bullement, A. orcid.org/0000-0001-7091-0972, D'Angelo, S.P., Amin, A. et al. (5 more authors) (2018) Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab. In: Journal of Clinical Oncology. 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, IL, USA. American Society of Clinical Oncology .